Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860092 · ClinicalTrials.gov registry record
New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System
A clinical trial, sponsored by Second Sight Medical Products.
- Terminated
- Registry status
- 53
- Enrollment target
NCT01860092: Clinical Trial study, sponsored by Second Sight Medical Products.
NCT01860092 is a clinical trial that was terminated before completion, run by Second Sight Medical Products. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01860092 was terminated before completion, sponsored by Second Sight Medical Products.
- TERMINATED
- Registry status
- 53 participants
- Enrollment target
Study Summary
This post-approval study is being implemented to monitor the use of Argus II System in a larger US population than available within pre-approval studies. An attempt will be made to include all eligible and willing subjects implanted with Argus II System in the United States.
Primary Outcome
Adverse event rates with the main safety analysis performed when all visits completed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-01 |
| Est. Completion | 2020-03 |
Why NCT01860092 stopped before completion
NCT01860092 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01860092 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01860092 about?
NCT01860092 is a clinical study titled "New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System". This post-approval study is being implemented to monitor the use of Argus II System in a larger US population than available within pre-approval studies. An attempt will be made to include all eligible and willing subjects implanted with Argus II System in the United States.
What is the current status of trial NCT01860092?
This trial is currently terminated. The enrollment target is 53 participants. The study started on 2014-01. Estimated completion is 2020-03.
Who is sponsoring clinical trial NCT01860092?
This trial is sponsored by Second Sight Medical Products, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia